AGIOS PHARMACEUTICALS

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

03 Jun 2024 09:51:53 By NetDania Notify

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

03 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

30 May 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AGIOS PHARMACEUTICALS INC. - COMMON STOCK

28 May 2024 09:45:31 By NetDania Notify

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

14 May 2024 10:00:00 By Nasdaq GlobeNewswire

Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

03 May 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2024 Financial Results

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

15 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

02 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

08 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

03 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

09 Dec 2023 19:00:00 By Nasdaq GlobeNewswire

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire